home / stock / sln / sln articles
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narro...
Silence Therapeutics Plc (NASDAQ:SLN) shares are trading lower in the morning session on Wednesday. The company reported a loss per share of (...
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. Shares of The Boeing Company (NYSE: BA) rose duri...
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 st...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...